Liquidia Corporation (LQDA)
| Market Cap | 5.42B +313.3% |
| Revenue (ttm) | 288.07M +1,936.7% |
| Net Income | 22.31M |
| EPS | 0.24 |
| Shares Out | 88.93M |
| PE Ratio | 249.79 |
| Forward PE | 14.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 974,108 |
| Open | 61.74 |
| Previous Close | 61.97 |
| Day's Range | 60.79 - 62.29 |
| 52-Week Range | 11.85 - 62.30 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 65.13 (+6.81%) |
| Earnings Date | May 11, 2026 |
About LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6... [Read more]
Financial Performance
In 2025, Liquidia's revenue was $158.32 million, an increase of 1031.18% compared to the previous year's $14.00 million. Losses were -$68.92 million, -46.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price target is $65.13, which is an increase of 6.81% from the latest price.
News
Liquidia Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
YUTREPIA's launch has driven rapid revenue growth and profitability, with expansion into PAH and PH-ILD markets supported by robust clinical data and ongoing studies. The pipeline, including L606, targets further innovation, while strong physician relationships and reinvestment in R&D underpin future growth.
Liquidia Transcript: Bank of America Global Healthcare Conference 2026
YUTREPIA's launch has exceeded expectations, achieving rapid revenue growth, expanding market share, and maintaining strong financial discipline. The company is investing in clinical studies, sales force expansion, and manufacturing to capture a $3–5 billion market opportunity, with a $1 billion revenue target for 2027.
Liquidia price target raised to $67 from $55 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Liquidia (LQDA) to $67 from $55 and keeps a Buy rating on the shares. Liquidia delivered a strong quarter…
Liquidia price target raised to $62 from $51 at Wells Fargo
Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $62 from $51 and keeps an Overweight rating on the shares. The firm says Yutrepia appears to be disrupting…
Liquidia price target raised to $60 from $57 at Jefferies
Jefferies analyst Amy Li raised the firm’s price target on Liquidia (LQDA) to $60 from $57 and keeps a Buy rating on the shares following “strong” Q1 results. The firm…
Liquidia Q1 Earnings Call Highlights
Liquidia NASDAQ: LQDA reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pul...
Liquidia Earnings Call Transcript: Q1 2026
YUTREPIA drove 44% sequential sales growth and tripled EBITDA in Q1 2026, achieving over $500M annualized run rate. Market share in inhaled prostacyclins neared 23%, with robust expansion in both PAH and PH-ILD segments. Management maintains confidence in reaching $1B revenue by 2027.
Liquidia Earnings release: Q1 2026
Liquidia released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Liquidia Quarterly report: Q1 2026
Liquidia has published its Q1 2026 quarterly earnings report on May 11, 2026.
Liquidia Slides: Q1 2026
Liquidia has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Liquidia reports Q1 EPS 52c, consensus 41c
Reports Q1 revenue $129.9M, consensus $119.4M. Cash and cash equivalents totaled $222.8M as of March 31, 2026, vs. $190.7M as of December 31, 2025. CEO Roger Jeffs said: “In its…
Liquidia Corporation Reports First Quarter 2026 Financial Results
YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients tr...
Liquidia Corporation to Participate in Upcoming Investor Conferences
MORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengin...
Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026
MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengin...
Liquidia Proxy statement: Proxy filing
Liquidia filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Liquidia Proxy statement: Proxy filing
Liquidia filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Liquidia Transcript: 25th Annual Needham Virtual Healthcare Conference
YUTREPIA has rapidly gained market share with strong patient uptake, robust financial performance, and broad prescriber adoption. Expansion of the sales force, new clinical studies, and a focus on displacing oral therapies are expected to drive growth toward a $1 billion revenue target by 2027. Legal and competitive dynamics remain important watchpoints.
Liquidia price target raised to $51 from $44 at Wells Fargo
Wells Fargo analyst Tiago Fauth raised the firm’s price target on Liquidia to $51 from $44 and keeps an Overweight rating on the shares. The firm believes the pulmonary hypertension…
Liquidia Technologies put volume heavy and directionally bearish
Bearish flow noted in Liquidia (LQDA) Technologies with 2,137 puts trading, or 1.1x expected. Most active are Apr-26 30 puts and Mar-26 20 puts, with total volume in those strikes…
Liquidia price target raised to $19 from $16 at Oppenheimer
Oppenheimer raised the firm’s price target on Liquidia (LQDA) to $19 from $16 and keeps an Underperform rating on the shares. The firm gives credit to the Liquidia team for…
Liquidia price target raised to $55 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Liquidia (LQDA) to $55 from $50 and keeps a Buy rating on the shares. The company’s “impressive” Q4 earnings support the view…
Liquidia files automatic mixed securities shelf
16:41 EST Liquidia (LQDA) files automatic mixed securities shelf
Liquidia Earnings Call Transcript: Q4 2025
YUTREPIA achieved rapid adoption and profitability, driving 74% sequential sales growth in Q4 2025 and expanding market share to 17%. Management projects continued momentum, robust cash flow, and targets $1 billion revenue by 2027, with ongoing clinical expansion.
Liquidia Annual report: Q4 2025
Liquidia has published its Q4 2025 annual report on March 5, 2026.